Advertisement

Medical Oncology

, 32:240 | Cite as

Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study

  • Xiaohui Zhang
  • Yidong Zhou
  • Feng Mao
  • Yan Lin
  • Jinghong Guan
  • Qiang SunEmail author
Original Paper

Abstract

This study aimed to evaluate the efficacy and safety of adjuvant chemotherapy with pirarubicin plus capecitabine (AX regimen) in Chinese node-negative breast cancer (BCa) patients. Two hundred eighty Chinese pT1-2N0M0 BCa patients under 70 years of age were equally and randomly assigned to receive four cycles of adjuvant therapy with the AX regimen or pirarubicin and cyclophosphamide (AC regimen) between January 2010 and May 2011. End points included overall survival (OS), disease-free survival (DFS), chemotherapy-induced toxicities, and quality of life (QoL). The 4-year DFS (AX vs. AC, 93.6 vs. 92.9 %, P = 0.761) and OS (97.1 vs. 96.4 %, P = 0.965) were similar between the two treatment arms. The AX group, compared to the AC group, experienced significantly less frequent grade III/IV vomiting (11.4 vs. 26.4 %, P < 0.001), whereas the incidence of other grade III/IV chemotherapy-associated toxicities was comparable between the two groups (all P values >0.05). Use of the AX regimen was associated with significantly higher QoL scores in the domains of physical, role, and social functions than the AC regimen (P values <0.05), although the two regimens were similar in the domains of emotional and cognitive functions (all P values >0.05). In comparison with the AC regimen, AX adjuvant chemotherapy is equally beneficial for node-negative BCa patients younger than 70 years with respect to OS and DFS. The AX regimen is primarily advantageous over the AC regimen based on less frequent severe toxicities and better health-related QoL.

Keywords

Node-negative breast cancer Adjuvant chemotherapy Survival Toxicity Quality of life Randomized, controlled study 

Notes

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi: 10.3322/caac.21208.CrossRefPubMedGoogle Scholar
  2. 2.
    Schmidt M, Koelbl H. Adjuvant chemotherapy in early breast cancer. Minerva Ginecol. 2012;64(1):53–65.PubMedGoogle Scholar
  3. 3.
    Fisher B, Jeong JH, Anderson S, Wolmark N. Treatment of axillary lymph node–negative, estrogen receptor–negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst. 2004;96(24):1823–31. doi: 10.1093/jnci/djh338.CrossRefPubMedGoogle Scholar
  4. 4.
    Goldstein LJ, O’Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008;26(25):4092–9. doi: 10.1200/jco.2008.16.7841.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Barrett-Lee P, Bidard FC, Pierga JY. Contemporary issues and the potential uses of capecitabine in metastatic breast cancer. Cancer Treat Rev. 2009;35(7):582–9. doi: 10.1016/j.ctrv.2009.06.003.CrossRefPubMedGoogle Scholar
  6. 6.
    Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11–8. doi: 10.1200/jco.2011.35.4639.CrossRefPubMedGoogle Scholar
  7. 7.
    Schellens JH. Capecitabine. Oncologist. 2007;12(2):152–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM, Tattersall MH. On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19(2):203–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Beusterien K, Grinspan J, Tencer T, Brufsky A, Visovsky C. Patient preferences for chemotherapies used in breast cancer. Int J Womens Health. 2012;4:279–87. doi: 10.2147/ijwh.s31331.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract. 1999;7(2):59–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M, Ferrans C, Cella D. The clinical significance of quality of life assessments in oncology: a summary for clinicians. Support Care Cancer. 2006;14(10):988–98. doi: 10.1007/s00520-006-0085-y.CrossRefPubMedGoogle Scholar
  12. 12.
    Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32. doi: 10.1186/1756-9966-27-32.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Lemieux J, Goodwin PJ, Bordeleau LJ, Lauzier S, Theberge V. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst. 2011;103(3):178–231. doi: 10.1093/jnci/djq508.CrossRefPubMedGoogle Scholar
  14. 14.
    Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102. doi: 10.1186/1477-7525-7-102.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wang Y, Yang H, Wei JF, Meng L. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials. Curr Med Res Opin. 2012;28(12):1911–9. doi: 10.1185/03007995.2012.748655.CrossRefPubMedGoogle Scholar
  16. 16.
    Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–65. doi: 10.1056/NEJMoa0810266.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Xiaohui Zhang
    • 1
  • Yidong Zhou
    • 1
  • Feng Mao
    • 1
  • Yan Lin
    • 1
  • Jinghong Guan
    • 1
  • Qiang Sun
    • 1
    Email author
  1. 1.Department of Breast Surgery, Peking Union Medical College HospitalChinese Academy of Medical Science and Peking Union Medical CollegeBeijingChina

Personalised recommendations